SCHEMBL3016409

SCHEMBL3016409

Cc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccccc4C(F)(F)F)CC3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
LMNA P02545 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
ALDH1A1 P00352 2/20 0.61
MAPT P10636 2/20 0.61
MAPK1 P28482 3/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
PKM P14618 1/20 0.50
GBA1 P04062 2/20 0.49
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
HTT P42858 1/20 0.48
AR P10275 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
HSD11B1 P28845 2/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007681 0.92 LMNA (0.63) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3009766 0.91 KMT2A (0.55) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3014667 0.90 MAPT (0.61) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3008167 0.89 KMT2A (0.58) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3007753 0.89 MAPT (0.58) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3010997 0.89 KMT2A (0.55) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3013918 0.89 KMT2A (0.55) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3116696 0.88 KMT2A (0.56) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3023065 0.87 LMNA (0.55) KMT2AMEN1LMNASMN1; SMN2ALDH1A1
SCHEMBL3015703 0.87 AR (0.54) KMT2AMEN1LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KMT2A 2680/4885MEN1 454/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.